From mouse to man: The early clinical testings

Drug Information Journal

Volumn 31, Issue 3, 1997, Pages 729-736

  Perry, Kimberly T ^a  

^a PFIZER INC   (United States)

Author keywords

Continual reassessment method; Maximum tolerance dose; Phase I; Study designs; Toxicity

Indexed keywords

ARTICLE; DRUG RESEARCH; DRUG SCREENING; MAXIMUM ALLOWABLE CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOCHASTIC MODEL;

EID: 0030833783     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100313     Document Type: Article

References (13)

1. Von Hoff D, Kuh J, Clark G. Design and Conduct of Phase I Trials. In Buyse ME, Staquet MJ, Sylvester RJ (eds). Cancer Clinical Trials: Methods and Practice. Oxford: Oxford University Press; 1984.
2. Geller NA. Design of Phase I and II Clinical Trials in Cancer: A Statistician's View. Cancer Invest. 1984; 2(6):483-491.
3. Gordon NH, Willson JKV. Using Toxicity Grades in the Design and Analysis of Cancer Phase I Clinical Trials. Stat Med. 1992;11:2063-2075.
4. Storer B, DeMets D. Current Phase I/II Designs: Are They Adequate? J Clin Res Drug Develop. 1987; 1:121-130.
5. Newell DR. Pharmacologically Based Phase I Trials in Cancer Chemotherapy. Hematol Oncol Clin North Am. 1994;8:257-275.
6. O'Quigley J, Chevret S. Methods for Dose Finding Studies in Cancer Clinical Trials: A Review and Results of a Monte Carlo Study. Stat Med. 1991;10: 1647-1664.
7. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A Comparison of Two Phase I Trial Designs. Stat Med. 1994;13:1799-1806.
8. O'Quigley J, Pepe M, Fisher L. Continual Reassessment Method: A Practical Design for Phase I Clinical Trial in Cancer. Biometrics. 1990;46:33-48.
9. Chevret S. The Continual Reassessment Method in Cancer Phase I Clinical Trials: A Simulation Study. Stat Med. 1993;12:1093-1108.
10. Storer BE. Design and Analysis of Phase I Clinical Trials. Biometrics. 1989;45:925-937.
11. Fanes D. Practical Modifications of the Continual Reassessment Method for Phase I Cancer Clinical Trials. J Biopharm Stat. 1994;4(2):147-164.
12. Moller S. An Extension of the Continual Reassessment Methods Using a Preliminary Up-and-Down Design in a Dose Finding Study in Cancer Patients, in order to Investigate a Greater Range of Doses. Stat Med. 1995;14:911-922.
13. Goodman SN, Zahurak ML, Piantadosi S. Some Practical Improvements in the Continual Reassessment Method for Phase I Studies. Stat Med. 1995; 14:1149-1161.